NCT05772286View on ClinicalTrials.gov

Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant HIV-1 Envelope Protein SOSIP v8.2 763 Vaccine, Adjuvanted With MPLA Liposomes, in Healthy, HIV-Uninfected Adults

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

July 24, 2023

Primary Completion Date

June 30, 2025

Study Completion Date

June 30, 2025

Conditions
Healthy
Interventions
BIOLOGICAL

763SIP8/MPLA-5 vaccine

763SIP8/MPLA-5 vaccine at day 0, week 8, week 24 and week 48.

Trial Locations (1)

08036

Hospital Clínic de Barcelona, Barcelona

Sponsors

Collaborators (1)

Polymun Scientific GmbH
All Listed Sponsors
collaborator

Polymun Scientific GmbH

INDUSTRY

lead

Fundacion Clinic per a la Recerca Biomédica

OTHER

NCT05772286 - Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant HIV-1 Envelope Protein SOSIP v8.2 763 Vaccine, Adjuvanted With MPLA Liposomes, in Healthy, HIV-Uninfected Adults | Biotech Hunter | Biotech Hunter